Northwest can only produce about 5 vaccines a month out of the London location.
Are you actually thinking that this small quantity of vaccines (5) would be sufficient to meet the demands of the specials program?
I'm sure we'd both agree that the London capacity certainly wouldn't be enough to meet the bigger UK/EU demand.
I'd think it would be better to have the Sawston facility ready to manufacture a much larger quantity of vaccines before they seek UK approval. And with top line intended to be completed sometime in September, they would likely seek UK approval soon after.
And if instead, they were to seek approval based on the teensy weensy lab space they rent out in London, I'd think the MHRA would be hesitant to approve them. I think the MHRA instead expects them to prove they have the ability to manufacture to at least meet the needs of the market. It was also very helpful that the Cambridgeshire & Peterborough Combined Authority offered them the "SPECIAL PURPOSE COMPETITIVE LOAN" amounting to additional funds of $1.77 million to help facilitate their build out. I'm betting they actually submitted for that loan about two years ago. And to think, it took this long to WIN it.
But if you still persist in thinking NWBO is a scam, then I could see why you'd think producing only five vaccines a month would be adequate for the company. I mean, why spend any money building out a much larger facility that you're already paying rent on to make more like a couple hundred vaccines a month, if all you care about, really, is having enough to make your pay check?
Market Data 
Markets 
AI
